Bleeding in patients treated with ticagrelor or clopidogrel before coronary artery bypass grafting

摘要: Background We evaluated perioperative bleeding after coronary artery bypass grafting (CABG) in patients preoperatively treated with ticagrelor or clopidogrel, stratified by discontinuation of these P2Y12 inhibitors. Methods All from the prospective, European Multicenter Registry on Coronary Artery Bypass Grafting (E-CABG) clopidogrel undergoing isolated primary CABG were eligible. The outcome measure was severe massive defined according to Universal Definition Perioperative Bleeding, inhibitor discontinuation. Secondary measures included four additional definitions major bleeding. Propensity score matching performed adjust for differences preoperative and covariates. Results Of 2,311 who included, 1,293 (55.9%) received 1,018 (44.1%) preoperatively. Mean time between operation 4.5 ± 3.2 days 4.9 3.0 ticagrelor. In propensity score–matched cohort, ticagrelor-treated had a higher incidence Bleeding when discontinued 0 2 compared 3 before (16.0% vs 2.7%, p = 0.003). Clopidogrel-treated 4 5 (15.6% 8.3%, 0.031). Conclusions receiving those CABG, there an increased rate Postponing nonemergent at least should be considered.